Eli Lilly shares rallied after the maker of Zepbound weight-control drug posted a 43% increase in quarterly revenue, blowing past Wall Street expectations. Danish rival Novo Nordisk compounded losses ...

GE HealthCare Technologies Inc (GEHC) reports robust Q4 performance with significant growth in pharmaceutical diagnostics and ...

GE HealthCare reported fourth-quarter earnings per share of $1.44 from sales of $5.7 billion. Wall Street was looking for ...

GEHC Q4 2025 earnings call recap: revenue, record backlog, 2026 guidance, Intelerad deal, Flyrcado ramp, tariffs & China risks—read key takeaways.

GE HealthCare (Nasdaq: GEHC) shares got a boost today on fourth-quarter results that came in ahead of the consensus forecast.

GE HealthCare beat earnings and revenue estimates, saw strong growth in imaging and drug units, managed tariff costs and ...

GE HealthCare posted full-year growth of 4.8% in 2025, including 7.1% revenue growth in its fourth quarter, beating analyst ...

The headline numbers for GE HealthCare (GEHC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Company exceeds topline and earnings per share expectations; demonstrates operational resilienceFourth quarter 2025 highlights(1)Revenue growth of 7.1%, including Organic revenue growth* of 4.8%, ...

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ...

Healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) reported Q4 CY2025 results exceeding the market’s ...

This collection of health news highlights includes GE HealthCare predicting a profit surge due to a high demand for diagnostic devices, Nestle expanding a recall due to toxin levels, advisories on ...